NCT07262320招募中不适用
Epidemiology and Processes of Care for Renal Replacement Therapy in Acute Kidney Injury in Latin America
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 1,000
- 试验地点
- 17
- 主要终点
- In-hospital mortality
研究概览
简要总结
This is an international, multicenter, observational study aimed at investigating acute kidney injury requiring renal replacement therapy (AKI-RRT) in Latin American countries. The main questions this study aims to answer are:
- What is the epidemiology, outcomes, and processes of care for patients with AKI-RRT in Latin America?
- How do outcomes differ across different countries in Latin America?
- What factors (demographics, clinical, socioeconomic) influence outcomes in patients with AKI-RRT in Latin America?
The main aims of this study are to:
- Establish a comprehensive database containing clinical, laboratory, treatment, process, and outcome data of patients with AKI-RRT in Latin America
- Describe current epidemiology of AKI-RRT in Latin America
- Compare processes of care and outcomes across different countries in Latin America
- Provide data resources to facilitate and promote clinical research in AKI-RRT
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adult patient (≥18) admitted to the ICU
- •First ICU admission during current hospitalization
- •Diagnosis of acute kidney injury stage 3 according to KDIGO guidelines
- •RRT initiated no earlier than 3 days before or no later than 7 days after ICU admission
排除标准
- •Transfer from outside hospital with ongoing RRT
- •RRT exposure of less than 2 days (if CRRT or PD was provided) or less than 2 HD/SLED sessions
- •Kidney failure (ESRD) patients on maintenance dialysis
- •Kidney transplant recipients
- •Previous or new diagnosis of glomerulonephritis
研究组 & 干预措施
Acute kidney injury patients requiring renal replacement therapy
Critically ill adult patients with acute kidney injury undergoing any form of renal replacement therapy in Latin American hospitals
结局指标
主要结局
In-hospital mortality
时间窗: From enrollment to hospital discharge or 90 days (whichever occurs first)
The variable is coded as 1 = deceased and 0 = alive by the time of hospital discharge
次要结局
- Length of stay in the ICU(From ICU admission to death or ICU discharge (truncated at 90 days))
- RRT dependence at follow-up(From RRT initiation (day 0) to 90-days post-ICU admission follow-up)
- RRT dependence at hospital discharge(From RRT initiation to hospital discharge or 90 days (whichever occurs first))
- Infectious complications associated with RRT(RRT initiation (day 0) to RRT day 6 or RRT termination (whichever occurs first))
- ICU mortality(From enrollment to ICU discharge or 90 days (whichever occurs first))
- 90-day follow-up mortality(From enrollment to 90-days post-ICU admission follow-up)
- Anticoagulation-related complications associated with RRT(RRT initiation (day 0) to RRT day 6 or RRT termination (whichever occurs first))
- Length of stay in the hospital(From hospital admission to death or hospital discharge (truncated at 90 days))
- Renal function recovery at follow-up(From enrollment to 90-days post-ICU admission follow-up)
- RRT-related procedural complications(RRT initiation (day 0) to RRT day 6 or RRT termination (whichever occurs first))
- Renal function recovery at hospital discharge(From enrollment to hospital discharge or 90 days (whichever occurs first))
研究者
Javier A. Neyra
Professor of Medicine
University of Alabama at Birmingham
研究点 (17)
Loading locations...
相似试验
Enrolling By Invitation
不适用
Demographic and Interpopulation Variations in Evaluation and Results of TAVIAortic StenosisNCT07258706Poznan University of Medical Sciences800
招募中
1 期
A PHASE 1B, MULTICENTER, RANDOMIZED, PLACEBO- CONTROLLED, DOUBLE-BLIND STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND BIOLOGICAL ACTIVITY OF TQS-168 IN SUBJECTS WITH AMYOTROPHIC LATERAL SCLEROSIS2023-504746-54-00Tranquis Therapeutics Inc.16
尚未招募
不适用
A Nationwide Multicenter, Single-arm, Retrospective Study of Delayed Endoscopic DTI-BR After Simple MastectomyBreast CancerNCT07257003Du Zhenggui150
进行中（未招募）
不适用
Multicenter, 8-week, Randomised, Double-Blind, Placebo Controlled Study of Two Doses of Depelestat in Cystic Fibrosis PatientsCystic fibrosisMedDRA version: 7.0Level: PTClassification code 10011762EUCTR2004-002341-12-DEDebiopharm SA90
进行中（未招募）
不适用
Multicenter, 8-week, Randomised, Double-Blind, Placebo Controlled Study of Two Doses of Depelestat in Cystic Fibrosis PatientsMedDRA version: 7.0Level: PTClassification code 10011762Cystic fibrosisEUCTR2004-002341-12-BEDebiopharm SA90